A clinical trial to study the effect of the drug Pippalyathi Mathirai in patients having Swasakasam(Bronchial Asthma)

Phase II Non-Randomized Open Clinical Evaluation of Siddha Medicine Pippalyathi Mathirai for the management of Swasakasam(Bronchial Asthma) - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/11/037968

Enrollment

Registered

2021-11-12

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: nil: nil Intervention2: Pippalyathi Mathirai: 1 tablet is administered twice a day with water for 48 days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Cough with tenacious sputum Dyspnoea H/O wheeze or without wheeze Chest tightness

Exclusion criteria

Exclusion criteria: Chronic Bronchitis Bronchiectasis Bronchogenic carcinoma Pulmonary TB Congestive cardiac failure Pregnancy and lactating mother Status asthmaticus Diabetes Mellitus

Design outcomes

Primary

Measure	Time frame
Primary outcome is mainly assessed by reduction in clinical symptoms and also byb assessing peak expiratory flow rate above 60% ensures the wellness of the patientTimepoint: 48days	—

Secondary

Measure	Time frame
Secondary outcome is mainly assessed by comparing the saved parameters before and after treatmentTimepoint: 48days	—

Countries

India

Contacts

Public ContactDr Chitra U

Government Siddha Medical College Chennai

mmsankar2000@gmail.com9025006404

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026